Kalaris Therapeutics Inc
NASDAQ Global MarketTotal Valuation
Kalaris Therapeutics Inc carries a market capitalization of 75.56M, placing it among publicly traded companies globally. Its enterprise value stands at 21.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 75.56M |
| Enterprise Value | 21.76M |
Share Statistics
Kalaris Therapeutics Inc currently has 22.99M shares outstanding.
| Shares Outstanding | 22.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.69 |
| P/TBV Ratio | 1.71 |
| P/FCF Ratio | -2.77 |
| P/OCF Ratio | -2.77 |
Financial Position
Kalaris Therapeutics Inc maintains a current ratio of 12.19, meaning it holds 12.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 12.19 |
| Quick Ratio | 12.03 |
| Debt / Equity | 2.06 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -41.43 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Kalaris Therapeutics Inc's stock has gained approximately 66.94215% over the past 52 weeks. The 50-day moving average sits at 4.61, while the 200-day moving average is 6.65.
| Beta (5Y) | N/A |
| 52-Week Price Change | 66.94215% |
| 50-Day Moving Average | 4.61 |
| 200-Day Moving Average | 6.65 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -47.61M, while operating income came in at -47.63M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -47.63M |
| Pretax Income | -44.10M |
| Net Income | -44.10M |
| EBITDA | -47.61M |
| EBIT | -47.63M |
| Earnings Per Share (EPS) | -2.16 |
Balance Sheet
Kalaris Therapeutics Inc holds 97.22M in cash and equivalents against 1.41M in total debt, resulting in a net debt position of -34.43M. Total book value stands at -170.85M, with working capital of 90.39M providing operational flexibility.
| Cash & Cash Equivalents | 97.22M |
| Total Debt | 1.41M |
| Net Debt | -34.43M |
| Equity (Book Value) | -170.85M |
| Book Value Per Share | -8.39 |
| Working Capital | 90.39M |
Cash Flow
Kalaris Therapeutics Inc produced -42.51M in operating cash flow over the past twelve months. After subtracting -17,000.00 in capital expenditures, free cash flow totaled -42.53M - equivalent to -2.09 per share.
| Operating Cash Flow | -42.51M |
| Capital Expenditures | -17,000.00 |
| Free Cash Flow | -42.53M |
| FCF Per Share | -2.09 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -39.16 |
| FCF Yield | -36.14 |
Stock Splits
Kalaris Therapeutics Inc's most recent stock split took place on January 16, 2025 with a 23:1 split ratio.
| Last Split Date | 1/16/2025 |
| Split Ratio | 23:1 |
Scores
Kalaris Therapeutics Inc posts an Altman Z-Score of -0.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.91 |